Literature DB >> 23482881

Rheumatic diseases and malignancies.

Violeta Bojinca1, Iustina Janta.   

Abstract

There are many studies which demonstrate a higher risk for malignancy in patients with rheumatic diseases. There have been a number of possible explanations for the differences in the risk of certain malignancies in patients with rheumatic disease, compared with general population, but a clear mechanism is difficult to identify.Rheumatoid syndromes may be associated with malignancy as paraneoplastic conditions, which can antedate the neoplasm diagnosis.On the other hand, autoimmune rheumatic diseases have a higher risk of malignancy by themselves or because of the immunosuppressant treatments.

Entities:  

Keywords:  malignancy; paraneoplastic syndromes; rheumatic disease

Year:  2012        PMID: 23482881      PMCID: PMC3593292     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  41 in total

1.  Long term safety of etanercept in elderly subjects with rheumatic diseases.

Authors:  R Fleischmann; S W Baumgartner; M H Weisman; T Liu; B White; P Peloso
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

Review 2.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

Review 3.  Exploring the links between systemic lupus erythematosus and cancer.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann Clarke
Journal:  Rheum Dis Clin North Am       Date:  2005-05       Impact factor: 2.670

4.  Malignancy and Rheumatic Disease.

Authors: 
Journal:  Cancer Control       Date:  1997-05       Impact factor: 3.302

5.  Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.

Authors:  Eva Szekanecz; Gabriella Szucs; Zoltán Szekanecz; Tünde Tarr; Péter Antal-Szalmás; Szilvia Szamosi; János Szántó; Emese Kiss
Journal:  J Autoimmun       Date:  2008-10-15       Impact factor: 7.094

6.  Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation?

Authors:  Eva Szekanecz; Zsuzsa Sándor; Péter Antal-Szalmás; Lilla Soós; Gabriella Lakos; Timea Besenyei; Agnes Szentpétery; Enikö Simkovics; János Szántó; Emese Kiss; Alisa E Koch; Zoltán Szekanecz
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

7.  Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Authors:  Johan Askling; Ronald F van Vollenhoven; Fredrik Granath; Pauline Raaschou; C Michael Fored; Eva Baecklund; Christina Dackhammar; Nils Feltelius; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Solbritt Rantapää-Dahlqvist; Tore Saxne; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2009-11

8.  Incidence of cancer among men with the Felty syndrome.

Authors:  G Gridley; J H Klippel; R N Hoover; J F Fraumeni
Journal:  Ann Intern Med       Date:  1994-01-01       Impact factor: 25.391

9.  Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.

Authors:  G R Burmester; P Mease; B A C Dijkmans; K Gordon; D Lovell; R Panaccione; J Perez; A L Pangan
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

10.  Prevalence of malignancy in psoriatic arthritis.

Authors:  Sherry Rohekar; Brian D M Tom; Agnes Hassa; Cathy T Schentag; Vernon T Farewell; Dafna D Gladman
Journal:  Arthritis Rheum       Date:  2008-01
View more
  9 in total

1.  The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.

Authors:  Yu-Chih Lin; Hui-Wen Chou; Wen-Chan Tsai; Jeng-Hsien Yen; Shun-Jen Chang; Yi-Ching Lin
Journal:  Clin Rheumatol       Date:  2015-05-20       Impact factor: 2.980

2.  Paraneoplastic cutaneous lupus secondary to esophageal squamous cell carcinoma.

Authors:  Thoyaja Koritala; Joseph Tworek; Brian Schapiro; Eugene Zolotarevsky
Journal:  J Gastrointest Oncol       Date:  2015-06

3.  Ontology-based systematic representation and analysis of traditional Chinese drugs against rheumatism.

Authors:  Qingping Liu; Jiahao Wang; Yan Zhu; Yongqun He
Journal:  BMC Syst Biol       Date:  2017-12-21

4.  Rheumatic manifestations as initial presentation of malignancy: A case series from a tertiary care center in India.

Authors:  Prasanta Padhan; Bhaskar Thakur; Pratima Singh; Ipsita Mohanty; Saroj Ranjan Sahoo
Journal:  Eur J Rheumatol       Date:  2018-12-13

5.  Malignant Peritoneal Mesothelioma Presenting with Polymyalgia Rheumatica-like Syndrome.

Authors:  Yuka Ide; Tsunetsugu Yuki; Yasuyuki Taooka; Yusuke Higashi; Yoshiro Tachiyama
Journal:  Intern Med       Date:  2020-06-23       Impact factor: 1.271

Review 6.  Targeting interleukin-1β and inflammation in lung cancer.

Authors:  Jun Zhang; Nirmal Veeramachaneni
Journal:  Biomark Res       Date:  2022-01-27

7.  Paget's disease of bone and megaloblastic anemia in a 72-year-old patient: A case report and systematic literature review.

Authors:  Violeta Diana Oprea; Violeta Claudia Bojincă; Andra-Rodica Bălănescu; Alin Laurențiu Tatu; Mihai Bojincă; Aurelia Romila
Journal:  Exp Ther Med       Date:  2022-02-08       Impact factor: 2.447

8.  Association between systemic sclerosis, palmar fasciitis with polyarthritis, Raynaud's phenomenon and erythromelalgia with underlying malignancy.

Authors:  Katarzyna Nowak; Gary Wright
Journal:  Reumatologia       Date:  2022-09-08

9.  Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis.

Authors:  Jian Wen; Han Ouyang; Ru Yang; Lin Bo; Yi Zhang; Mei Tang; Zhichun Liu
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.